Further Darzalex results extend hope for PFS in Myeloma
Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its primary endpoint and was stopped early as recommended by the Independent Data Monitoring Committee.
This trial compared the compared the safety and efficacy of Darzalex, Velcade (bortezomib; Takeda) and dexamethasone (DVd) versus Velcade and dexamethasone (Vd) in subjects with relapsed or refractory multiple myeloma, with qualitative results indicating a positive outcome.
In April the company released further information, giving some sense of the magnitude of improvement that this combination could achieve, results that were reported in the media as ‘substantially – some might even say dramatically’ extending progression-free survival in relapsed multiple myeloma patients.
Today (June 5th) at the 2016 annual meeting of the American Society for Clinical Oncology (ASCO), data were presented from the prespecified interim analysis of the CASTOR trial. Jay Grisolano and Greg Wolfe of Kantar Health were present and have released a report on this paper.
To view more coverage on pharmaphorum of the ASCO 2016 conference click here.